Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:KIN

Kindred Biosciences (KIN) Stock Price, News & Analysis

Kindred Biosciences logo

About Kindred Biosciences Stock (NASDAQ:KIN)

Advanced Chart

Key Stats

Today's Range
$9.24
$9.26
50-Day Range
$9.08
$9.25
52-Week Range
$3.46
$9.28
Volume
178,496 shs
Average Volume
840,890 shs
Market Capitalization
$420.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive KIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kindred Biosciences and its competitors with MarketBeat's FREE daily newsletter.

KIN Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
Kindred Hospital East Greensboro
Japan's Sony terminates $10 bln Zee India merger
European Shares Edge Higher With ECB Meeting In The Spotlight
Earnings Optimism May Contribute To Continued Strength On Wall Street
See More Headlines

KIN Stock Analysis - Frequently Asked Questions

Kindred Biosciences, Inc. (NASDAQ:KIN) announced its quarterly earnings data on Thursday, August, 5th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.16) by $0.04. The biopharmaceutical company earned $3.54 million during the quarter, compared to the consensus estimate of $8.12 million. Kindred Biosciences had a negative net margin of 529.26% and a negative trailing twelve-month return on equity of 54.19%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kindred Biosciences investors own include CorMedix (CRMD), Sorrento Therapeutics (SRNE), Micron Technology (MU), bluebird bio (BLUE), Novavax (NVAX), Bristol Myers Squibb (BMY) and Meta Platforms (META).

Company Calendar

Last Earnings
8/05/2021
Today
7/15/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KIN
CIK
1561743
Fax
N/A
Employees
63
Year Founded
2013

Profitability

EPS (Trailing Twelve Months)
($0.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$21.80 million
Net Margins
-529.26%
Pretax Margin
N/A
Return on Equity
-54.19%
Return on Assets
-39.76%

Debt

Debt-to-Equity Ratio
0.19
Current Ratio
7.02
Quick Ratio
7.02

Sales & Book Value

Annual Sales
$42.16 million
Price / Sales
9.97
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.75 per share
Price / Book
5.29

Miscellaneous

Outstanding Shares
45,462,000
Free Float
N/A
Market Cap
$420.52 million
Optionable
Optionable
Beta
1.30

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:KIN) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners